Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Celldex Therapeutics clinical trials
The registry lists 51 studies whose lead sponsor is Celldex Therapeutics or one of 2 companies grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
Keep track of what changes. Save the Celldex Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Celldex Therapeutics.
- Celldex Therapeutics45 studiesSame company
Something wrong?
- CuraGen Corporation4 studies →Acquired — became part of Celldex Therapeutics, Oct 1, 2009 · source ↗
Something wrong?
- Avant Immunotherapeutics2 studies →Acquired — became part of Celldex Therapeutics, Mar 7, 2008 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →
- Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaEnrolling by invitationNCT07256392Phase 3
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)RecruitingNCT07266402Phase 3
- A Study of CDX-622 in Participants With Mild to Moderate AsthmaRecruitingNCT07330778Phase 1
- A Study of Barzolvolimab in Patients With Atopic DermatitisActive, not recruitingNCT06727552Phase 2
- A Study of Barzolvolimab in Patients With Prurigo NodularisActive, not recruitingNCT06366750Phase 2
- A Study of CDX-0159 in Patients With Eosinophilic EsophagitisCompletedNCT05774184Phase 2
- A Phase I Study of CDX-622CompletedNCT06650761Phase 1
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaActive, not recruitingNCT06445023Phase 3
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Active, not recruitingNCT06455202Phase 3
- A Study of CDX-0159 in Patients With Chronic Inducible UrticariaCompletedNCT05405660Phase 2
- A Study of CDX-585 in Patients With Advanced MalignanciesCompletedNCT05788484Phase 1
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedNCT05368285Phase 2
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
- A Study of CDX-0159 in Patients With Prurigo NodularisCompletedNCT04944862Phase 1
- A Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaCompletedNCT04538794Phase 1
- A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesCompletedNCT04440943Phase 1
- A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic UrticariaCompletedNCT04548869Phase 1
- A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT03254927Phase 2
- A Phase 1 Study of Subcutaneous CDX-0159 in Healthy SubjectsCompletedNCT05031624Phase 1
- A Phase 1 Study of CDX-0159CompletedNCT04146129Phase 1
- A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaTerminatedNCT02837991Phase 1
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive GlioblastomaCompletedNCT01498328Phase 2
- A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)TerminatedNCT01094496Phase 2
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsCompletedNCT02335918Phase 1/2
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedNCT02302339Phase 2
- A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer PatientsCompletedNCT02473731Phase 1
- A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid TumorsCompletedNCT02642016Phase 1
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast CancerCompletedNCT01997333Phase 2
- A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT02386111Phase 1
- Individual Patient Expanded Access-Glembatumumab VedotinNo longer availableNCT03067935
- A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerTerminatedNCT02543645Phase 1
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedNCT01460134Phase 1
- Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma MultiformeCompletedNCT00458601Phase 2
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaCompletedNCT01480479Phase 3
- Expanded Access (Compassionate Use) Treatment Protocol RindopepimutNo longer availableNCT03068650
- Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379CompletedNCT02456701Phase 1
- A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced TumorsCompletedNCT02014909Phase 1
- A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast CancerCompletedNCT01156753Phase 2
- A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy VolunteersCompletedNCT01465139Phase 1
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedNCT02413827Phase 1/2
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
- A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1CompletedNCT00948961Phase 1/2
- A Phase II Controlled Trial of Velafermin for Prevention of Oral MucositisCompletedNCT00323518Phase 2
Sponsor listed in the registry: CuraGen Corporation · First submitted before CuraGen Corporation became part of Celldex Therapeutics
- Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow TransplantCompletedNCT00104065Phase 2
Sponsor listed in the registry: CuraGen Corporation · First submitted before CuraGen Corporation became part of Celldex Therapeutics
- Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast CancerCompletedNCT00704158Phase 1/2
Sponsor listed in the registry: CuraGen Corporation · First submitted before CuraGen Corporation became part of Celldex Therapeutics
- A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT00412828Phase 1/2
Sponsor listed in the registry: CuraGen Corporation · First submitted before CuraGen Corporation became part of Celldex Therapeutics
- Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseTerminatedNCT01791686Phase 1
- A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)CompletedNCT00709462Phase 1
- Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian CancerCompletedNCT00648102Phase 1
- Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult SubjectsCompletedNCT00498654Phase 2
Sponsor listed in the registry: Avant Immunotherapeutics · First submitted before Avant Immunotherapeutics became part of Celldex Therapeutics